Crossmark

Bortezomib in MCL—new standard of care or just another option?

Crossref DOI link: https://doi.org/10.1038/nrclinonc.2015.101

Published Online: 2015-05-26

Published Print: 2015-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dreyling, Martin
License Information

Text and Data Mining valid from 2015-05-26
More Information

Article History

First Online: 26 May 2015

Competing interests

: M.D. declares institutional support of clinical trials by Celgene, Janssen, Pfizer, Roche. M.D. has served on the scientific advisory boards of Celgene and Janssen, and has received speakers' honouraria from Celgene, Janssen, Mundipharma, Pfizer, and Roche.